Nanobiosys Inc. | Date: 2016-04-26
Optical apparatus and instruments, namely, fluorescence photometry and lab-on-a-chip image detector; densitometers, namely, densitometer for measuring the density of nucleic acid, virus, and bacteria for scientific use; saccharometers; testing apparatus not for medical purposes, namely, laboratory glassware for the isolation of nucleic acid; testing apparatus not for medical purposes, namely, laboratory isolator for the isolation of nucleic acid; testing apparatus not for medical purposes, namely, laboratory centrifuges for the isolation of nucleic acid; testing apparatus not for medical purposes, namely, laboratory burettes for extracting nucleic acid; testing apparatus not for medical purposes, namely, laboratory chemical reactors for mixing nucleic acid; testing apparatus not for medical purposes, namely, beakers for mixing nucleic acid; diagnostic apparatus for detecting nucleic acid for laboratory or research use; diagnostic apparatus for detecting nucleic acid solution temperature for laboratory or research use; diagnostic apparatus for testing food for laboratory or research use; diagnostic apparatus for the detection of pathogens for laboratory or research use; incubators for bacteria culture; food analysis apparatus, namely, diagnostic apparatus for testing food; food analysis apparatus, namely, laboratory devices for detecting genetic sequences for gene analysis; food analysis apparatus, namely, electrical equipment for the genetic modification of cells for research purposes for use in gene analysis; DNA chips; precision measuring apparatus, namely, lasers for fluorescence photometry to analyze nucleic acid, and fluorescence photometry; dosage dispensers, namely, mechanical devices in the nature of dispensers of preset portions of fluids, solid granules and powder for dosing purposes, all not for medical use; computer chips; semiconductor chips; testing apparatus not for medical purposes, namely, laboratory apparatus and instruments for extracting nucleic acid; testing apparatus not for medical purposes, namely, plastic chip-type containers for mixing nucleic acid. Medical machines and apparatus, namely, medical apparatus for detecting infectious diseases, viral disease, bacterial diseases, respiratory diseases, foodborne diseases, waterborne diseases, sepsis and food poisoning; medical apparatus and instruments other than for dental purposes, namely, medical apparatus for detecting infectious diseases in animals, Medical apparatus for diagnosing or treating respiratory conditions in animals, medical diagnostic instruments for the analysis of body fluids in animals.
Nanobiosys Inc. | Date: 2014-08-07
A nucleic acid extraction device, which can realize automation, ultra-miniaturization and super-high speed in the nucleic acid extraction reaction, has no limitation to the type of biological specimens that can be used, such as sputum, blood, cells, urine, saliva, tissues, etc., minimize the used amount of the sample solution, and also maintain and/or improve the nucleic acid extraction efficiency with reliability.
Nanobiosys Inc. | Date: 2011-04-22
According to the present invention, a PCR device including two heating blocks which is used for nucleic acid amplification reactions is disclosed. Using the PCR device of the present invention, nucleic acid amplification reactions can be efficiently performed.
Song H.-O.,Wonkwang University |
Kim J.-H.,Wonkwang University |
Ryu H.-S.,NanoBioSys Inc. |
Lee D.-H.,NanoBioSys Inc. |
And 7 more authors.
It is clinically important to be able to detect influenza A/H1N1 virus using a fast, portable, and accurate system that has high specificity and sensitivity. To achieve this goal, it is necessary to develop a highly specific primer set that recognizes only influenza A viral genes and a rapid real-time PCR system that can detect even a single copy of the viral gene. In this study, we developed and validated a novel fluidic chip-type real-time PCR (LabChip real-time PCR) system that is sensitive and specific for the detection of influenza A/H1N1, including the pandemic influenza strain A/H1N1 of 2009. This LabChip real-time PCR system has several remarkable features: (1) It allows rapid quantitative analysis, requiring only 15 min to perform 30 cycles of real-time PCR. (2) It is portable, with a weight of only 5.5 kg. (3) The reaction cost is low, since it uses disposable plastic chips. (4) Its high efficiency is equivalent to that of commercially available tube-type real-time PCR systems. The developed disposable LabChip is an economic, heat-transferable, light-transparent, and easy-to-fabricate polymeric chip compared to conventional silicon- or glass-based labchip. In addition, our LabChip has large surface-to-volume ratios in micro channels that are required for overcoming time consumed for temperature control during real-time PCR. The efficiency of the LabChip real-time PCR system was confirmed using novel primer sets specifically targeted to the hemagglutinin (HA) gene of influenza A/H1N1 and clinical specimens. Eighty-five human clinical swab samples were tested using the LabChip real-time PCR. The results demonstrated 100% sensitivity and specificity, showing 72 positive and 13 negative cases. These results were identical to those from a tube-type real-time PCR system. This indicates that the novel LabChip real-time PCR may be an ultra-fast, quantitative, point-of-care-potential diagnostic tool for influenza A/H1N1 with a high sensitivity and specificity. © 2012 Song et al. Source
Lee S.H.,KEPCO E&C |
Kim S.-W.,NanoBioSys Inc. |
Lee S.,NanoBioSys Inc. |
Kim E.,NanoBioSys Inc. |
And 8 more authors.
BACKGROUND: NBS LabChip G2-3 is a novel, ultrafast, chip-type portable real-time polymerase chain reaction (PCR) system. We evaluated the clinical usefulness of this system in detecting pulmonary TB and assessed its diagnostic performance compared witha conventional tube-type PCR system. METHODS: A total of 247 sputum samples were collected from patients suspected of having pulmonary TB. After the decontamination process, these samples were examined by fluorescence staining for acid-fast bacilli, cultures with both solid and liquid media, and real-time PCR with the NBS LabChip and a conventional tube-type system. The diagnostic accuracy of the NBS LabChip system and the agreement between the two assays were evaluated. RESULTS: Considering mycobacterial culture results as a gold standard, the overall sensitivity and specificity of the NBS LabChip was 83.8% (95% CI, 73.8%-91.1%) and 94.0% (95% CI, 89.3%-97.1%), respectively. For the detection of TB from the smear-positive samples, the sensitivity and specificity of the NBS LabChip was 96.0% (95% CI, 86.3%-99.5%) and 83.3% (95% CI, 72.3%-95.7%), respectively. For the smear-negative samples, the sensitivity and specificity of the NBS LabChip was 63.3% (95% CI, 43.9%-80.1%) and 95.0% (95% CI, 90.4%-97.8%), respectively. There were no significant differences in the sensitivity and specificity between the NBS LabChip and a conventional tube-type system, although the NBS LabChip shortened the PCR time (27 min for 45 cycles). CONCLUSIONS: The NBS LabChip G2-3 system has potential as an ultrafast, cost-effective diagnostic tool for pulmonary TB with high sensitivity and specificity. © 2014 American College of Chest Physicians. Source